cGvHD Symposium 2024 congress coverage

Catch up with our live social media coverage of cGvHD updates from the cGvHD Symposium 2024.

CONGRESS | #cGvHD2024 | POSTER
A poster by Jingbo Yu, et al. presented analysis of treatment patterns of ruxolitinib (rux) and corticosteroids (CS) in the US. Early rux initiation led to greater CS reduction, and 33.1% of patients continued rux for at least 1 year #GVHD pic.twitter.com/OY1dxNhvbY

— GvHD Hub (@gvhd_hub) October 25, 2024

CONGRESS | #cGvHD2024 | POSTER
A poster by Gagan Raju, et al. presented results from a real-world study, which found that in patients with advanced SR/SD cGvHD, belumosudil treatment led to high response rates and survival outcomes #GvHD pic.twitter.com/YZjSMNevhs

— GvHD Hub (@gvhd_hub) October 25, 2024

CONGRESS | #cGvHD2024
Juliana Roden spoke about PROs in routine care - a standardised approach would be useful. Administering PRO questionnaires can be labour intensive - using an app could allow a wider reach. However, challenges including translation to other languages and… pic.twitter.com/Mz6Vjaf9GJ

— GvHD Hub (@gvhd_hub) October 17, 2024

CONGRESS | #cGvHD2024
Eric Tkaczyk discussed use of AI for skin cGvHD assessment. Experts may disagree on BSA for a patient, making it difficult to train an AI model. AI has the potential to detect changes that may be missed, but currently under-performs in underrepresented skin… pic.twitter.com/gwKbBWmEXu

— GvHD Hub (@gvhd_hub) October 17, 2024

CONGRESS | #cGvHD2024 @MeredithCowden spoke about Perspectives in GvHD Patients and HCPs. Patients want to build a good relationship with their HCP - communication is key. Collaboration in treatment can help that patient to feel heard. #GvHD pic.twitter.com/sOwLdCsWLh

— GvHD Hub (@gvhd_hub) October 17, 2024

CONGRESS | #cGvHD2024 @Hschoemans discussed PROs in trials. Patients with poor QoL may be more likely to switch treatment, leading to poorer outcomes. Better treatments are needed to improve QoL in cGvHD, with regular use of PROs to understand patient perspective. #GvHD pic.twitter.com/QvoWz2Hwne

— GvHD Hub (@gvhd_hub) October 17, 2024

CONGRESS | #cGvHD2024
Edwin Horwitz discussed MSC Therapy for cGvHD. Preclinical models may not translate into human patients, but initial clinical trials have positive results. The long-term outcomes with MSCs are unknown, but it may be better as a prophylaxis rather than a… pic.twitter.com/zy6w3YD2OS

— GvHD Hub (@gvhd_hub) October 17, 2024

CONGRESS | #cGvHD2024
Madeline Lauener spoke about NK cells in GvHD. Regulatory NKs are of interest in cGvHD. Studies suggest higher NK cell numbers reduces GvHD risk. There are distinct differentiation pathways of NK cells amongst HSCT recipients with and without #GvHD. pic.twitter.com/cDdxjX324L

— GvHD Hub (@gvhd_hub) October 17, 2024

CONGRESS | #cGvHD2024
Christian Stockman discussed vaccine-based immunotherapy for fibrosis. Vaccination targeting ADAM-12 expressing cells reduces liver fibrosis in mice, ADAM-12 could also be targeted in the skin. GLI1 transcription factor immunisation in mice showed fibrosis… pic.twitter.com/SKHs4YcsZV

— GvHD Hub (@gvhd_hub) October 17, 2024

CONGRESS | #cGvHD2024
Daniel Wolff spoke about highly morbid forms of GvHD. Clinical trials of highly morbid forms can be costly and have difficulty recruiting patients. Incorporating PROs and experimental assessments into observational studies may be helpful. #GvHD pic.twitter.com/XGsYNxpkm4

— GvHD Hub (@gvhd_hub) October 16, 2024

CONGRESS | #cGvHD2024
Kirsten Williams discussed etiology and prevention of cGvHD from NIH 2020 consensus. Prevention of cGvHD could result in higher relapse rates. Balance between immune regulatory and effector cells is key. Therefore, patients should have a longer follow-up… pic.twitter.com/Cuqw8s2jCH

— GvHD Hub (@gvhd_hub) October 16, 2024

CONGRESS | #cGvHD2024
Joseph Pidala and Geoff Hill spoke about pre-emptive therapy from the 2020 NIH consensus. There is progress on risk assessment biomarkers, with published data and more studies underway. IL-17 monocyte signature in mice could be leveraged to give insights… pic.twitter.com/uJgejYTo3l

— GvHD Hub (@gvhd_hub) October 16, 2024

CONGRESS | #cGvHD2024 @DrCCutler discussed clinical implementation and early diagnosis from the 2020 NIH consensus. Progress has been made in educating patients, caregivers, and providers. Early diagnosis remains a priority, but there are no trials on PROs to predict onset of… pic.twitter.com/suQTEH2ORq

— GvHD Hub (@gvhd_hub) October 16, 2024

CONGRESS | #cGvHD2024 @DrZackDeFilipp spoke about the treatment of cGvHD from the 2020 NIH consensus. Larger trials lack correlative analyses, and there is a need for innovative trial design. Steroid-free monotherapies in the first line are lacking but should remain a long-term… pic.twitter.com/7Dg0YHKnp1

— GvHD Hub (@gvhd_hub) October 16, 2024

CONGRESS | #cGvHD2024
Jacqueline Mays discussed how tissue biomarkers can help guide cGVHD treatment. The ROCKstar trial measured IL-17 in 20 patients, and found belumosudil decreased IL-17 and collagen in the oral mucosa. More studies are needed to compare tissue and blood… pic.twitter.com/Y2aQUWgwyz

— GvHD Hub (@gvhd_hub) October 16, 2024

CONGRESS | #cGvHD2024@sophpacz discussed predictive biomarkers in GvHD. Biomarkers are able to predict cGvHD risk at Day 90 post-HCT, and ideally biomarkers should be utilised as early as possible to stratify high-risk patients. All treatments should have biomarkers developed,… pic.twitter.com/IXtCKkiDMb

— GvHD Hub (@gvhd_hub) October 16, 2024

Only 1 day to go!
The GvHD Hub will be covering the 7th International Chronic Graft-versus-Host Disease Symposium!

Oct 16–17
Vancouver, CA and online

We’ll be providing live social media coverage – keep an eye on our socials for the latest updates.#gvhdsm #cGvHD2024 pic.twitter.com/mThaK1rQvX

— GvHD Hub (@gvhd_hub) October 14, 2024